ImmunityBio, Inc. research snapshot
IBRX AI stock analysis currently sees ImmunityBio as a newly commercial immunotherapy company with real ANKTIVA revenue growth but an unproven path to durable profitability. At the July 12, 2026 research cutoff, the latest verified close was $8.22 on July 10 and the market capitalization was about $8.61 billion, calculated from the close and 1.047 billion shares outstanding. FY2025 revenue reached $113.3 million and Q1 2026 revenue reached $44.2 million, yet the company remained loss-making, used $75.4 million of operating cash in Q1, and carried large convertible and revenue-interest obligations. The central question is whether ANKTIVA adoption, international launches, and label expansion can outrun cash burn, dilution, clinical risk, and valuation compression. This page is informational research only and is not investment advice.
Current price
$8.22
Market cap
$8.61 billion
AI score
46 / 100
Rating
Commercial traction, but financing and execution risk dominate
Trend status
Above the 50-day and 200-day averages, with high biotech volatility
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | ImmunityBio has moved from development to commercialization with ANKTIVA, but the business is still concentrated in one early product and one core oncology franchise. | Medium-high |
| Moat | The potential moat is the IL-15 platform, regulatory approvals, clinical evidence, manufacturing know-how, and patents. Adoption and long-term differentiation are not yet proven. | Medium |
| Management | Founder-scientist Patrick Soon-Shiong and CEO Richard Adcock combine scientific and commercial leadership, but related-party financing, concentrated ownership, and communication risk require close monitoring. | Medium |
| Financial trend | Revenue rose from $14.75 million in 2024 to $113.29 million in 2025, and Q1 2026 revenue rose 168% year over year to $44.21 million. Losses and operating cash use remain substantial. | High for reported data |
| Valuation | At about 60.55x trailing revenue with negative EPS and negative free cash flow, the price requires strong future sales growth and successful financing. | Medium-high |
| Technical trend | IBRX was above its 50-day average of $7.76 and 200-day average of $5.52, while RSI near 58.89 was constructive rather than overbought. | Medium-high |
| Risk level | Risk is high because clinical and regulatory outcomes, product adoption, financing, dilution, debt-like obligations, and sharp biotech price gaps can all change the thesis quickly. | High |
| AI confidence | Confidence is strongest for the approved indication, filings, cash use, share count, and current technical snapshot. Confidence is low for future returns and clinical probabilities. | Medium-high for facts |
| Investment certainty | Investment certainty is low to medium. The company has a real commercial foothold, but the balance sheet and pipeline still make the outcome asymmetric and difficult to underwrite. | Low-medium |
IBRX AI stock forecast
The IBRX AI stock forecast uses conditional price bands rather than a fixed target. A PE-based model is not meaningful while EPS and free cash flow are negative, so these ranges are research scenarios tied to revenue adoption, approvals, cash needs, and dilution. They are not promises and should be recalculated after every filing or major clinical and regulatory event.
$12 to $18
More likely if ANKTIVA revenue continues to compound, international launches become material, the BCG-naive sBLA advances on schedule, clinical readouts support label expansion, and financing is achieved without severe dilution.
$5 to $10
More likely if revenue keeps growing but commercialization costs, R&D, revenue-interest payments, and equity issuance remain high, leaving investors to value IBRX on execution rather than current earnings.
$1.50 to $4
More likely if ANKTIVA uptake slows, trials or regulatory reviews disappoint, cash needs force unfavorable financing, dilution accelerates, or debt-like obligations reduce the value available to common shareholders.
IBRX AI technical analysis
IBRX AI technical analysis uses the July 10, 2026 close and the latest public technical snapshot reviewed on July 12. Price was above both major moving averages, but the stock remains a high-volatility biotech name with a wide 52-week range. Confirm all levels on a live chart before acting because this static page does not fetch request-time market data.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $8.22 | Latest verified close on July 10, 2026, used for the July 12 research cutoff. |
| Near support | $7.70 to $7.80 | Planning zone around the reported 50-day moving average of $7.76. |
| Secondary support | $5.50 to $5.60 | Planning zone around the reported 200-day moving average of $5.52. |
| Near resistance | $9.00 to $9.10 | The July 9 high was $9.09. A breakout needs stronger participation than the recent average. |
| 52-week resistance | $12.40 to $12.43 | The upper end of the reported 52-week range and a major supply area if price rallies. |
| 50-day moving average | $7.76 | Latest StockAnalysis statistics snapshot reviewed July 12, 2026. |
| 200-day moving average | $5.52 | Latest StockAnalysis statistics snapshot reviewed July 12, 2026. |
| Momentum | RSI 58.89 | Constructive but not extreme in the reviewed snapshot. RSI can change quickly after biotech news. |
| Volume | 12.79 million shares; 20-day average 12.95 million | July 10 volume was close to the reported average, so a sustained breakout should show expanding participation. |
| Volatility and invalidation | High; close below $7.70, then $5.50 | The 52-week range was $1.95 to $12.43. A close below the 50-day area weakens the near-term trend; a break below the 200-day area challenges the long trend. |
IBRX AI trading strategy
The IBRX AI trading strategy is a rules-based research framework, not personalized advice. It combines price confirmation with product revenue, cash use, financing, regulatory events, and clinical milestones because technical signals alone can fail around biotech catalysts.
Treat a move above $9.00 to $9.10 as technically stronger only if volume expands and the company continues to report ANKTIVA adoption and cash discipline.
A failed breakout or daily close below the $7.70 to $7.80 support zone reduces confidence in the setup.
If IBRX pulls back toward the 50-day area while revenue, regulatory progress, and liquidity remain intact, compare price stabilization with the next filing before considering a mean-reversion thesis.
Do not average down only because the stock is below a recent high. Define a maximum loss and review dilution and financing risk first.
Monitor quarterly ANKTIVA revenue, international commercial availability, the BCG-naive sBLA, clinical readouts, cash runway, ATM issuance, warrant exercises, and FDA communications.
Binary events can create gaps through any stop. Use position sizing and event exposure limits that match the possibility of a rapid loss.
Investment research summary
ImmunityBio develops and commercializes immunotherapies that aim to activate the immune system. The current business is anchored by ANKTIVA plus BCG for an FDA-approved subset of high-risk non-muscle invasive bladder cancer.
The potential moat is a combination of IL-15 platform know-how, regulatory approval, clinical data, manufacturing capabilities, intellectual property, and physician familiarity. It is narrower and less proven than the moat of an established pharmaceutical franchise.
The thesis can fail if physician adoption slows, the approved market remains small, label expansion misses, clinical data disappoints, regulatory scrutiny damages demand, financing becomes punitive, or revenue-interest and debt obligations absorb the commercial upside.
Patrick Soon-Shiong provides founder and scientific leadership while Richard Adcock leads as president and CEO. The company has executed an ANKTIVA launch and expanded trials, but related-party debt, concentrated ownership, warrants, and equity issuance create governance and dilution questions.
Oncology immunotherapy is a long-term medical trend, but it is crowded and evidence-driven. IBRX participates in a large potential market while the near-term addressable market remains limited by approved indications, reimbursement, competition, and trial success.
At about 60.55x trailing revenue, negative EPS, negative free cash flow, and a market capitalization far above current annual sales, the stock price implies years of successful growth. The margin of safety depends on execution and financing, not current earnings power.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| IBRX price | $8.22, July 10, 2026 close | StockAnalysis historical prices | July 12, 2026 |
| Market capitalization | $8.61 billion, verified as $8.22 x 1.047 billion shares with 0.01% calculation variance | StockAnalysis and financial_rigor.py | July 12, 2026 |
| Shares outstanding | 1,047.34 million at March 31, 2026, excluding treasury shares | ImmunityBio Q1 2026 Form 10-Q | July 12, 2026 |
| FY2025 revenue | $113.29 million in StockAnalysis, approximately $113.0 million in the company release, up about 700% year over year | StockAnalysis and ImmunityBio FY2025 release | July 12, 2026 |
| Q1 2026 revenue | $44.21 million, up 168% year over year | ImmunityBio Q1 2026 results and StockAnalysis cross-check | July 12, 2026 |
| Cash and marketable securities | $380.88 million at March 31, 2026 | ImmunityBio Q1 2026 Form 10-Q and StockAnalysis | July 12, 2026 |
| Debt-like obligations | $1.08 billion of convertible note and revenue-interest liabilities at March 31, 2026; StockAnalysis reports $1.12 billion total debt | ImmunityBio Q1 2026 Form 10-Q and StockAnalysis | July 12, 2026 |
| Operating cash use | $75.36 million in Q1 2026 and $304.94 million in FY2025 | ImmunityBio Q1 2026 Form 10-Q and FY2025 Form 10-K | July 12, 2026 |
| Valuation math | P/S about 60.55x; P/E and P/FCF are not meaningful with negative EPS and free cash flow | StockAnalysis statistics and financial_rigor.py | July 12, 2026 |
| Technical inputs | 50-day MA $7.76, 200-day MA $5.52, RSI 58.89, 20-day average volume 12.95 million, short interest 12.90% | StockAnalysis statistics | July 12, 2026 |
| Founder and affiliate ownership | Approximately 62.5% of common stock outstanding at March 31, 2026 | ImmunityBio Q1 2026 Form 10-Q | July 12, 2026 |
| Regulatory communication risk | The FDA issued a March 2026 warning letter addressing promotional communications about ANKTIVA | U.S. Food and Drug Administration | July 12, 2026 |
| Approved indication | ANKTIVA plus BCG approved for BCG-unresponsive NMIBC with CIS, with or without papillary tumors | U.S. Food and Drug Administration | July 12, 2026 |
This IBRX AI stock analysis page is an informational research tool only. It is not investment advice, financial advice, tax advice, a recommendation, or a promise of future returns. Forecast ranges are scenarios based on public filings, quote snapshots, technical data, regulatory information, and third-party sources reviewed through July 12, 2026. They may be wrong, incomplete, or outdated after new earnings, product sales, financing, clinical data, regulatory decisions, market moves, or macro conditions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
